Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

NVAX), a biotechnology company with a current market capitalization of $1.03 billion and annual revenue of $682 million, has renegotiated the terms of its collaboration with Takeda Pharmaceutical ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 6.86%, which has investors questioning if this is right time to buy.

Novavax, Inc. (NASDAQ:NVAX), a biotechnology company with a current market capitalization of $1.03 billion and annual revenue of $682 million, has renegotiated the terms of its collaboration with ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call ...